Who owns BridgeBio Pharma, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of BBIO from SEC Form 13F filings across 475 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 475 institutions disclosed 193.6M shares of BridgeBio Pharma, Inc. worth $14.60B — about 98.9% of shares outstanding; the largest disclosed holder is Jupiter Topco LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
475
13F holders
$14.60B
value, 2026 filers
98.9%
of shares outstanding (193.6M sh)
91
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of BBIO's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | Jupiter Topco LLCNEW | 14.1M | $1.05B | 0.4% | 7.2% | new |
| 2 | Kohlberg Kravis Roberts & Co. L.P. | 13.3M | $987.7M | 17.3% | 6.8% | 0.0% |
| 3 | FARALLON CAPITAL MANAGEMENT, L.L.C. | 10.7M | $800.1M | 3.7% | 5.5% | +14.7% |
| 4 | BlackRock, Inc. | 10.3M | $766.2M | 0.0% | 5.3% | -27.6% |
| 5 | VIKING GLOBAL INVESTORS LP | 9.9M | $741.0M | 2.1% | 5.1% | -16.0% |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 7.9M | $588.3M | 0.0% | 4% | +1.8% |
| 7 | VANGUARD PORTFOLIO MANAGEMENT LLC | 7.7M | $570.3M | 0.0% | 3.9% | -5.2% |
| 8 | WELLINGTON MANAGEMENT GROUP LLP | 5.3M | $395.4M | 0.1% | 2.7% | +113.7% |
| 9 | TWO SIGMA INVESTMENTS, LP | 4.7M | $351.7M | 0.3% | 2.4% | +51.3% |
| 10 | Aisling Capital Management LP | 4.6M | $341.8M | 72.5% | 2.3% | -9.8% |
| 11 | STATE STREET CORP | 4.4M | $330.4M | 0.0% | 2.3% | -10.1% |
| 12 | CITADEL ADVISORS LLC | 3.8M | $280.0M | 0.0% | 1.9% | +18.5% |
| 13 | Invesco Ltd. | 3.7M | $275.6M | 0.0% | 1.9% | -19.4% |
| 14 | D. E. Shaw & Co., Inc. | 3.6M | $270.6M | 0.1% | 1.9% | +42.7% |
| 15 | GEODE CAPITAL MANAGEMENT, LLC | 3.4M | $254.7M | 0.0% | 1.7% | -30.5% |
| 16 | JANE STREET GROUP, LLC | 2.9M | $218.5M | 0.0% | 1.5% | +66.9% |
| 17 | JPMORGAN CHASE & CO | 2.4M | $173.2M | 0.0% | 1.2% | +82.7% |
| 18 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.3M | $167.7M | 0.2% | 1.2% | +276.0% |
| 19 | FRANKLIN RESOURCES INC | 2.2M | $160.9M | 0.0% | 1.1% | -11.4% |
| 20 | Polar Capital Holdings Plc | 2.1M | $153.7M | 0.4% | 1.1% | -18.1% |
| 21 | FMR LLC | 2.1M | $153.5M | 0.0% | 1.1% | -12.1% |
| 22 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 2.0M | $145.7M | 0.1% | 1% | -1.1% |
| 23 | SC US (TTGP), LTD. | 1.9M | $138.6M | 0.4% | 1% | 0.0% |
| 24 | GOLDMAN SACHS GROUP INC | 1.8M | $135.2M | 0.0% | 0.9% | -4.4% |
| 25 | UBS Group AG | 1.8M | $130.9M | 0.0% | 0.9% | -13.3% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.